v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues [Abstract]    
Revenue $ 70,874 $ 52,443
Operating expenses    
Cost of revenue 18,708 16,979
Research and development 23,623 24,203
Sales and marketing 26,346 23,047
General and administrative 20,984 17,399
Amortization of intangible assets 419 419
Total operating expenses 90,080 82,047
Loss from operations (19,206) (29,604)
Interest and other income, net 2,080 2,679
Interest expense (2,889) (2,905)
Net loss (20,015) (29,830)
Add: Net income attributable to noncontrolling interest (18) (22)
Net loss attributable to Adaptive Biotechnologies Corporation $ (20,033) $ (29,852)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (0.13) $ (0.2)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (0.13) $ (0.2)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 155,521,048 149,195,028
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 155,521,048 149,195,028